| Company Name: |
LGM Pharma
|
| Tel: |
1-(800)-881-8210 |
| Email: |
inquiries@lgmpharma.com |
| Products Intro: |
Product Name:Reteplase
CAS:133652-38-7
Purity:Typically NLT 98%
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
4008200310 |
| Email: |
marketing@tsbiochem.com |
| Products Intro: |
Product Name:Reteplase
CAS:133652-38-7
Purity:98% Package:100 mg；5 mg；50 mg
|
|
| | Reteplase Basic information |
| | Reteplase Chemical Properties |
| | Reteplase Usage And Synthesis |
| Description | Reteplase was launched in Germany and the US for acute myocardial
infarction. Retevase is a single chain recombinant form of tissue plasminogen
activator (t-PA) with all except the kringle-2 and protease domains deleted. When
expressed in E. coli the inactive form is produced and stored in inclusion bodies.
After purification and an in vitro refolding process the active form is obtained. The
expression in E. coli gives rise to a non-glycosylated protein. This and the deletion of
several domains allows reteplase to have a longer half-life and a slower clearance.
Despite the deletions and refolding the catalytic center remains intact. The kringle-2
domain allows binding to lysine in fibrin which makes it effective for the rapid and
complete lysis of coronary thrombi. While it does not have a high affinity for binding
to fibrin, its activity is stimulated by it and has the same level of in vivo fibrin
selectivity as human t-PA. It has a low affinity for endothelial cells and can be
administered as a double bolus injection. Netaplase, a similar recombinant form of t-
PA, was launched by MitsuiIMochida in Japan. | | Originator | Boehringer Mannheim (Germany) | | Uses | Myocardial infarction therapy; plasminogen activator. | | Brand name | Retavase | | General Description | Reteplase (Retavase) is a deletion mutant variant of tPAthat is produced in recombinant E. coli. The deletions arein domains responsible for half-life, fibrin affinity, andthrombolytic potency. It consists of the kringle-2 domain and protease domain of tPA but lacks the kringle-1 domainand the growth factor domain. It is considered a thirdgenerationthrombolytic agent and has a mechanism of actionsimilar to that of alteplase. Reteplase acts directly bycatalyzing the cleavage of plasminogen and initiatingthrombolysis. It has high thrombolytic potency. | | Mechanism of action | Reteplase is a recombinant deletion mutant of tPA lacking the finger, epidermal growth factor,
kringle 1 domain, and carbohydrate side chain. As a highly fibrin-specific
thrombolytic agent, reteplase is missing the first 172 amino acids that are present in alteplase and
has 355 amino acids with a molecular weight of 39 kDa. Because of the removal of the finger kringle
1 domain, reteplase binding to fibrin is reduced from that of alteplase, and reteplase has reduced
fibrin selectivity. In addition, the structural modification reduces hepatic elimination, leading to a
longer half-life (reteplase, 14–18 minutes; alteplase, 3–4 minutes). | | Clinical Use | Administered as a double bolus of 10 U every 30 minutes, reteplase is approved for use in acute
myocardial infarction. | | Drug interactions | Potentially hazardous interactions with other drugs
Antiplatelets, heparin, vitamin K antagonists:
increased risk of bleeding. | | Metabolism | Cleared primarily by liver and kidneys. |
| | Reteplase Preparation Products And Raw materials |
|